Betamethasone dipropionate is under clinical development by Oticara and currently in Phase II for Rhinosinusitis. According to GlobalData, Phase II drugs for Rhinosinusitis have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Betamethasone dipropionate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Betamethasone dipropionate overview
Betamethasone dipropionate is under development for the treatment of eosinophilic chronic rhinosinusitis (eCRS). It acts by targeting glucocorticoid receptor. It is administered through nasal route.
Oticara is an developer of therapeutics ear and sinus conditions. The items created are Otic to get otitis externa caused due bacterial and contagious microorganisms. It is headquartered in Austin, Texas, the US.
For a complete picture of Betamethasone dipropionate’s drug-specific PTSR and LoA scores, buy the report here.